New technologies and techniques for prostate cancer focal therapy

Linares-Espinós, Estefanía; Carneiro, Ariê; Martínez-Salamanca, Juan Ignacio; Bianco, Fernando J.; Castro-Alfaro, Adalberto; Cathelineau, Xavier; Valério, Massimo; Sánchez-Salas, Rafael

doi:10.23736/s0393-2249.18.03094-1

Cited by 21 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recent increase in screening measures has led to the detection of prostate cancers at earlier stages, calling into question the current standard treatments of radical prostatectomy, high dose prostate brachytherapy, and external beam radiation therapy that target the whole-gland prostate and reduce quality of life [ 158 , 159 ]. New treatments have been developed that aim to achieve both tumor control and functional preservation by partial ablation of the prostate while sparing the structures crucial for genitourinary function [ 158 ].…”

Section: Prostate Tumorsmentioning

confidence: 99%

Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors

et al. 2022

View full text Add to dashboard Cite

Image-guided percutaneous ablation methods have been further developed during the recent two decades and have transformed the minimally invasive and precision features of treatment options targeting primary and metastatic tumors. They work by percutaneously introducing applicators to precisely destroy a tumor and offer much lower risks than conventional methods. There are usually shorter recovery periods, less bleeding, and more preservation of organ parenchyma, expanding the treatment options of patients with cancer who may not be eligible for resection. Image-guided ablation techniques are currently utilized for the treatment of primary and metastatic tumors in various organs including the liver, pancreas, kidneys, thyroid and parathyroid, prostate, lung, bone, and soft tissue. This article provides a brief review of the various imaging modalities and available ablation techniques and discusses their applications and associated complications in various organs.

show abstract

Section: Prostate Tumorsmentioning

confidence: 99%

Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…181 (3) Histotripsy: involves US waves in short bursts (lasting from micro-to milliseconds) at high pressures of more than 15 MPa and with a low duty cycle <5%, which causes mechanical effects due to coagulative thermal damage. 182 Histotripsybased trials by Hu and coworkers depicted that histotripsy could be used to increase CD-11c + cells by 1.3-folds, and a 2fold increase in DCs takes place for draining into LN as compared to thermal US group. 183 Further investigation resulted in the categorization of histotripsy under two mechanical effects.…”

Section: Enhancing Cancer Immunotherapymentioning

confidence: 99%

Enhancing Cancer Immunotherapeutic Efficacy with Sonotheranostic Strategies

et al. 2021

View full text Add to dashboard Cite

Immunotherapy has revolutionized the modality for establishing a firm immune response and immunological memory. However, intrinsic limitations of conventional low responsive poor T cell infiltration and immune related adverse effects urge the coupling of cancer nanomedicines with immunotherapy for boosting antitumor response under ultrasound (US) sensitization to mimic dose-limiting toxicities for safe and effective therapy against advanced cancer. US is composed of high-frequency sound waves that mediate targeted spatiotemporal control over release and internalization of the drug. The unconventional US triggered immunogenic nanoengineered arena assists the limited immunogenic dose, limiting toxicities and efficacies. In this Review, we discuss current prospects of enhanced immunotherapy using nanomedicine under US. We highlight how nanotechnology designs and incorporates nanomedicines for the reprogramming of systematic immunity in the tumor microenvironment. We also emphasize the mechanical and biological potential of US, encompassing sonosensitizer activation for enhanced immunotherapeutic efficacies. Finally, the smartly converging combinational platform of US stimulated cancer nanomedicines for amending immunotherapy is summarized. This Review will widen scientists' ability to explore and understand the limiting factors for combating cancer in a precisely customized way.

show abstract

“…To date, focal therapy (FT) is emerging as a valid curative option, providing reasonable oncological outcomes, and limiting the typical side effects of radical surgery or external beam radiotherapy (ERBT) [ 2 – 4 ]. Based on these evidence, partial gland cryoablation (PGC) is gaining an increasing interest among PCa therapies due to its encouraging oncological and functional results [ 5 , 6 ]. However, several main issues concerning FT are still under investigation.…”

Section: Introduction and Aim Of The Studymentioning

confidence: 99%

Treatment of localized prostate cancer in elderly patients: the role of partial cryoablation

et al. 2023

View full text Add to dashboard Cite

Purpose To evaluate oncological outcomes of partial gland cryoablation (PGC) for localized prostate cancer (PCa) in a cohort of elderly patients who required an active treatment. Methods Data from 110 consecutive patients treated with PGC for localized PCa were collected. All patients underwent the same standardized follow-up with serum-PSA level and digital rectal examination. Prostate MRI and eventual re-biopsy were performed at twelve months after cryotherapy or in case of suspicion of recurrence. Biochemical recurrence was defined according to Phoenix criteria (PSA nadir + 2 ng/ml). Kaplan–Meier curves and Multivariable Cox Regression analyses were used to predict disease progression, biochemical recurrence- (BCS) and additional treatment-free survival (TFS). Results Median age was 75 years (IQR 70–79). PGC was performed in 54 (49.1%) patients with low-risk PCa, 42 (38.1%) with intermediate risk and 14 (12.8%) high risk. At a median follow-up of 36 months, we recorded a BCS and TFS of 75 and 81%, respectively. At 5 years, BCS was 68.5% and CRS 71.5%. High-risk prostate cancer was associated with lower TFS and BCS curves when compared with low-risk group (all p values < .03). A PSA reduction < 50% between preoperative level and nadir resulted as an independent failure predictor for all outcomes evaluated (all p values < .01). Age was not associated with worse outcomes. Conclusions PGC could be a valid treatment for low- to intermediate PCa in elderly patients, when a curative approach is suitable in terms of life expectancy and quality of life.

show abstract

New technologies and techniques for prostate cancer focal therapy

Cited by 21 publications

References 0 publications

Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors

Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors

Enhancing Cancer Immunotherapeutic Efficacy with Sonotheranostic Strategies

Treatment of localized prostate cancer in elderly patients: the role of partial cryoablation

Contact Info

Product

Resources

About